First Use of AXL Targeting in Metastatic, Refractory, Adenoid Cystic Carcinoma: A Case Report
Conditionally Active Biologic (CAB) ADCs with Novel NextGen Linker Show Improved Efficacy and Safety
Novel Conditionally Active Biologic Tetravalent T-Cell Engagers Targeting Solid Tumors
Development of A Humanized Anti-IL-22 Antibody for Cancer and Inflammation Therapy
Conditionally Active Biologics Targeting Novel Senescence Markers Effectively Eliminate the Senescence-Associated Secretory Phenotype in both In Vitro and in Vivo Models
Results from a Phase 2 Part 1 Trial of Mecbotamab Vedotin (BA3011), a CAB-AXL-ADC, in Patients with Advanced Refractory Sarcoma
A Novel Conditional Active Biologic Anti-EpCAM x Anti-CD3 Bispecific Antibody with Synergistic Tumor Selectivity for Cancer Immunotherapy
Phase 2 Trial of Mecbotamab Vedotin (BA3011), a CAB-AXL-ADC, Alone or in Combination With Nivolumab in Patients With Non-Squamous NSCLC
A Novel Dual CAB Nectin-4 x CD3 Bispecific Antibody Targeting Solid Tumors
Generating tumor-selective conditionally active biologic anti-CTLA4 antibodies via protein-associated chemical switches
